CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F22%3A00129740" target="_blank" >RIV/00216224:14110/22:00129740 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/22:00077516
Result on the web
<a href="http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7769&category_id=180&option=com_virtuemart" target="_blank" >http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7769&category_id=180&option=com_virtuemart</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/neo_2022_220504N477" target="_blank" >10.4149/neo_2022_220504N477</a>
Alternative languages
Result language
angličtina
Original language name
CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity
Original language description
Chimeric antigen receptor (CAR)-T cells are a new treatment modality in various hematological malignancies, including relapsed/refractory multiple myeloma (RRMM). RRMM patients have a poor prognosis, and their treatment options are limited. Currently available data from clinical trials on CAR-T cell therapy have demonstrated efficacy and manageable toxicity in RRMM. The CAR-T cells in RRMM mostly focus on already known cellular targets, such as B-cell maturation antigen (BCMA). CAR-T cells focusing on other targets have been analyzed in various clinical trials as well. Cytokine release syndrome (CRS), specific neurotoxicity, and hematological toxicity are the main adverse events (AE); according to the clinical trials, they are mostly mild with a low incidence of grade 3 or higher toxicities. The autologous CAR-T cell therapy against BCMA (ide-cel and cilta-cel) shows the best efficacy with an overall response rate and a median progression-free survival in RRMM. Both ide-cel and cilta-cel have already been approved by the FDA. Currently, the main controversies in the routine use of CAR-T cells are high treatment costs and unknown long-term efficacy. In this review, we summarize the current overview of CAR-T cell therapies in RRMM in 2021 with various targets for CAR-T cells and their efficacy, safety, and possible limitations. Future prospective clinical trials are needed to clarify the optimal role of CAR-T cells in MM therapy.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NU21-03-00076" target="_blank" >NU21-03-00076: Using MALDI-TOF mass spectrometry for identification of molecular patterns in relapsed multiple myeloma patients</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neoplasma
ISSN
0028-2685
e-ISSN
1338-4317
Volume of the periodical
69
Issue of the periodical within the volume
5
Country of publishing house
SK - SLOVAKIA
Number of pages
11
Pages from-to
1008-1018
UT code for WoS article
001065035900002
EID of the result in the Scopus database
2-s2.0-85140144337